Hims & Hers Health (HIMS) shares are down for a fourth consecutive day, trading at $45.53, as the company prepares to release Q3 results after market close on November 3rd. The stock is nearing a historically bullish technical trendline, which has previously indicated an average 18.2% gain within a month in 75% of similar occurrences. Despite a mixed post-earnings history and predominantly pessimistic analyst ratings (11 of 14 at 'hold' or worse), this bearish sentiment could provide room for upgrades, especially given HIMS's tendency to outperform options traders' volatility expectations.
Shares of Hims & Hers Health (HIMS) are currently experiencing a four-day decline, trading at $45.53, as the market anticipates its Q3 earnings release after market close on November 3rd. This recent pullback follows rallies that stalled around $65 after the stock reached a February record high of $72.98. The equity is nearing a historically bullish technical trendline, specifically within 0.75 of the 200-day moving average's 20-day average true range. This pattern has previously resulted in an average 18.2% gain one month later in three out of four instances, suggesting a potential short-term bounce towards $51.45. HIMS has a mixed post-earnings performance, with the stock finishing lower after four of its last eight reports, including a 12.4% drop in August, and an average next-day swing of 13.3%. Investors are currently pricing in a higher 17.1% move for the upcoming report. Analyst sentiment remains largely pessimistic, with 11 of 14 analysts holding a "hold" or worse rating, which could provide significant room for upgrades should Q3 results surprise positively. Additionally, HIMS tends to outperform options traders' volatility expectations, as indicated by its Schaeffer's Volatility Scorecard (SVS) of 80.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mixed
Sentiment Score
0.10
Ticker Sentiment
